Market Overview

Recap: Intra-Cellular Therapies Q2 Earnings


Shares of Intra-Cellular Therapies (NASDAQ:ITCI) fell 2% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 41.18% year over year to ($0.96), which missed the estimate of ($0.91).

Revenue of $1,907,000 higher by 0.00% from the same period last year, which missed the estimate of $3,030,000.


Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Aug 10, 2020

Time: 08:30 AM

ET Webcast URL:

Recent Stock Performance

52-week high: $43.56

52-week low: $6.75

Price action over last quarter: Up 7.13%

Company Overview

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.


Related Articles (ITCI)

View Comments and Join the Discussion!

Posted-In: Earnings News